NCT01649427View on ClinicalTrials.gov

Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

October 17, 2012

Primary Completion Date

August 20, 2015

Study Completion Date

August 20, 2015

Conditions
Pharmacokinetics Study in de Novo Kidney Transplantation
Interventions
DRUG

Prograf

Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.

DRUG

Tacrolimus Hexal

"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."

Trial Locations (5)

10098

Novartis Investigative Site, Berlin

40225

Novartis Investigative Site, Düsseldorf

44892

Novartis Investigative Site, Bochum

51109

Novartis Investigative Site, Koeln-Merheim

67655

Novartis Investigative Site, Kaiserslautern

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY